Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy

被引:36
|
作者
Crossen, Karl [1 ]
Jones, Marsha [1 ]
Erikson, Christopher [1 ]
机构
[1] North Mississippi Med Ctr, Tupelo, MS USA
关键词
Ablation; Radiofrequency; Hypertrophic obstructive cardiomyopathy; Interventricular septum; Left ventricular outflow tract; SUBAORTIC STENOSIS; ABLATION;
D O I
10.1016/j.hrthm.2016.04.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Alcohol septal ablation remains the only approved nonsurgical therapeutic alternative for patients with drug-resistant hypertrophic obstructive cardiomyopathy (HOCM). Radiofrequency (RF) ablation offers another option for treating HOCM. OBJECTIVE The purpose of this study was to determine whether irrigated RF ablation can reduce symptomatic outflow tract obstruction in adults with HOCM. METHODS Patients with symptomatic HOCM and an outflow gradient of >50 mm Hg despite medication were offered RF ablation. In 11 patients, the hypertrophied interventricular septum was localized on a 3-dimensional mapping system and ablated via a transmitral or retrograde aortic approach. RESULTS Ten of 11(91%) patients had a significant and persistent reduction in resting and provocable left ventricular outflow tract gradients. Mean resting gradients at 12 months postprocedure were reduced by 85% (66.7 mm Hg at baseline to 10.0 mm Hg at 12 months); mean provocable gradients were reduced by 85% from baseline (136.2 mm Hg at baseline to 20.0 mm Hg at 12 months). Functional New York Heart Association heart classification improved from class 3.0 +/- 0.0 in all patients to class mean of 1.8 +/- 0.8. CONCLUSION RF septal ablation for the treatment of HOCM is a safe therapeutic option that allows for significant reduction in left ventricular outflow tract gradients, improvement in symptoms, and increase in efficacy rates comparable to reported rates for alcohol septal ablation.
引用
收藏
页码:1885 / 1890
页数:6
相关论文
共 50 条
  • [21] Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy
    Sedehi, Daniel
    Finocchiaro, Gherardo
    Tibayan, Yen
    Chi, Jeffrey
    Pavlovic, Aleksandra
    Kim, Young M.
    Tibayan, Frederick A.
    Reitz, Bruce A.
    Robbins, Robert C.
    Woo, Joseph
    Ha, Richard
    Lee, David P.
    Ashley, Euan A.
    JOURNAL OF CARDIOLOGY, 2015, 66 (1-2) : 57 - 62
  • [22] Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
    Patlolla, Sri Harsha
    Schaff, Hartzell V.
    Nishimura, Rick A.
    Eleid, Mackram F.
    Geske, Jeffrey B.
    Ommen, Steve R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (01):
  • [23] Costs and Healthcare Resource Utilization for Obstructive Hypertrophic Cardiomyopathy With Septal Reduction Therapy br
    Butzner, Michael
    Maron, Martin S.
    Sarocco, Phil
    Teng, Chia-Chen
    Stanek, Eric
    Tan, Hiangkiat
    Robertson, Laura A.
    JOURNAL OF INVASIVE CARDIOLOGY, 2022, 34 (12) : E866 - E872
  • [24] Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy
    Sorajja, Paul
    Valeti, Uma
    Nishimura, Rick A.
    Ommen, Steve R.
    Rihal, Charanjit S.
    Gersh, Bernard J.
    Hodge, David O.
    Schaff, Hartzell V.
    Holmes, David R., Jr.
    CIRCULATION, 2008, 118 (02) : 131 - 139
  • [25] Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience
    Rastegar, Hassan
    Boll, Griffin
    Rowin, Ethan J.
    Dolan, Noreen
    Carroll, Catherine
    Udelson, James E.
    Wang, Wendy
    Carpino, Philip
    Maron, Barry J.
    Maron, Martin S.
    Chen, Frederick Y.
    ANNALS OF CARDIOTHORACIC SURGERY, 2017, 6 (04) : 353 - 363
  • [26] Effects of surgical septal myectomy on survival in patients with hypertrophic obstructive cardiomyopathy
    Meng, Xiangbin
    Liang, Mingyu
    Shi, Yong-en
    Zhang, Weijie
    Zhou, Sijie
    Gao, Chuanyu
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2020, 23 (06) : 342 - 348
  • [27] Unjailing of the Septal Perforator Using a Rotational Atherectomy Device Prior to Alcohol Septal Ablation in a Patient with Symptomatic Hypertrophic Obstructive Cardiomyopathy
    Basir, Babar
    Greenbaum, Adam
    O'Neill, William
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2014, 84 (03) : E26 - E29
  • [28] Percutaneous septal ablation in hypertrophic obstructive cardiomyopathy
    Faber, Lothar
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2006, 11 (10) : 423 - 431
  • [29] Study design and rationale of VALOR-HCM : evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy
    Desai, Milind Y.
    Wolski, Kathy
    Owens, Anjali
    Naidu, Srihari S.
    Geske, Jeffrey B.
    Smedira, Nicholas G.
    Schaff, Hartzell
    Lampl, Kathy
    McErlean, Ellen
    Sewell, Christina
    Zhang, David
    Edelberg, Jay M.
    Sehnert, Amy J.
    Nissen, Steven E.
    AMERICAN HEART JOURNAL, 2021, 239 : 80 - 89
  • [30] Non-surgical methods of septal myocardial reduction for hypertrophic obstructive cardiomyopathy
    Dabrowski, Maciej
    Chojnowska, Lidia S.
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2008, 4 (02): : 68 - 73